The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 

Marc Cohen

Division of Cardiology

Newark Beth Israel Medical Center

201 Lyons Avenue at Osborne Terrace

Newark

[email]@sbhcs.com

Name/email consistency: high

 
 
 
 
 
 
 

Affiliations

  • Division of Cardiology, Newark Beth Israel Medical Center, 201 Lyons Avenue at Osborne Terrace, Newark. 2003 - 2012
  • Division of Cardiology, MCP Hahnemann University School of Medicine, PA, Philadelphia, USA. 2003

References

  1. Appropriate anti-thrombotic/anti-thrombin therapy for thrombotic lesions. Iqbal, Z., Rana, G., Cohen, M. Curr. Cardiol. Rev (2012) [Pubmed]
  2. Therapy for ST-segment elevation myocardial infarction patients who present late or are ineligible for reperfusion therapy. Cohen, M., Boiangiu, C., Abidi, M. J. Am. Coll. Cardiol. (2010) [Pubmed]
  3. The thrombin hypothesis in ACS: a disappointing disconnect between bench data and bedside clinical trials. Cohen, M. Am. J. Med. (2010) [Pubmed]
  4. Enoxaparin 0.3 mg/kg IV supplement for patients transitioning to PCI after subcutaneous enoxaparin therapy for NSTE ACS: a subgroup analysis from the SYNERGY trial. Cohen, M., Levine, G.N., Pieper, K.S., Lan, L., Antman, E.M., Aylward, P.E., White, H.D., Kleiman, N.S., Califf, R.M., Mahaffey, K.W. Catheter. Cardiovasc. Interv (2010) [Pubmed]
  5. Oral antiplatelet therapy for acute and chronic management of NSTE ACS: residual ischemic risk and opportunities for improvement. Cohen, M. Cardiovasc. Drugs. Ther (2009) [Pubmed]
  6. Expanding the recognition and assessment of bleeding events associated with antiplatelet therapy in primary care. Cohen, M. Mayo Clin. Proc. (2009) [Pubmed]
  7. Antiplatelet therapy in percutaneous coronary intervention: a critical review of the 2007 AHA/ACC/SCAI guidelines and beyond. Cohen, M. Catheter. Cardiovasc. Interv (2009) [Pubmed]
  8. Re-evaluating risk factors for periprocedural complications during percutaneous coronary intervention in patients with unstable angina/non-ST-elevation myocardial infarction: who may benefit from more intensive antiplatelet therapy?. Cohen, M., Ferguson, J.J. Curr. Opin. Cardiol. (2009) [Pubmed]
  9. The use of adjunctive anticoagulants in patients with acute coronary syndrome transitioning to percutaneous coronary intervention. Cohen, M., Hoekstra, J. Am. J. Emerg. Med (2008) [Pubmed]
  10. Bleeding after antithrombotic therapy in patients with acute ischemic heart disease: is it the drugs or how we use them?. Cohen, M., Alexander, K.P., Rao, S.V. J. Thromb. Thrombolysis (2008) [Pubmed]
  11. Pathophysiology and disease progression of atrial fibrillation: importance of achieving and maintaining sinus rhythm. Cohen, M., Naccarelli, G.V. J. Cardiovasc. Electrophysiol. (2008) [Pubmed]
  12. High-risk acute coronary syndrome patients with non-ST-elevation myocardial infarction: definition and treatment. Cohen, M. Cardiovasc. Drugs. Ther (2008) [Pubmed]
  13. Pharmacoinvasive management of acute coronary syndrome: incorporating the 2007 ACC/AHA guidelines: the CATH (cardiac catheterization and antithrombotic therapy in the hospital) Clinical Consensus Panel Report--III. Cohen, M., Diez, J.E., Levine, G.N., Ferguson, J.J., Morrow, D.A., Rao, S.V., Zidar, J.P. J. Invasive. Cardiol (2007) [Pubmed]
  14. Randomized, double-blind, dose-ranging study of otamixaban, a novel, parenteral, short-acting direct factor Xa inhibitor, in percutaneous coronary intervention: the SEPIA-PCI trial. Cohen, M., Bhatt, D.L., Alexander, J.H., Montalescot, G., Bode, C., Henry, T., Tamby, J.F., Saaiman, J., Simek, S., De Swart, J. Circulation (2007) [Pubmed]
  15. A subgroup analysis of the impact of prerandomization antithrombin therapy on outcomes in the SYNERGY trial: enoxaparin versus unfractionated heparin in non-ST-segment elevation acute coronary syndromes. Cohen, M., Mahaffey, K.W., Pieper, K., Pollack, C.V., Antman, E.M., Hoekstra, J., Goodman, S.G., Langer, A., Col, J.J., White, H.D., Califf, R.M., Ferguson, J.J. J. Am. Coll. Cardiol. (2006) [Pubmed]
  16. Predictors of bleeding risk and long-term mortality in patients with acute coronary syndromes. Cohen, M. Curr. Med. Res. Opin (2005) [Pubmed]
  17. Low-molecular-weight heparin in patients with acute ST-segment elevation myocardial infarction. Cohen, M. Am. Heart. Hosp. J (2005) [Pubmed]
  18. The role of gender and other factors as predictors of not receiving reperfusion therapy and of outcome in ST-segment elevation myocardial infarction. Cohen, M., Gensini, G.F., Maritz, F., Gurfinkel, E.P., Huber, K., Timerman, A., Santopinto, J., Corsini, G., Terrosu, P., Joulain, F. J. Thromb. Thrombolysis (2005) [Pubmed]
  19. The evolution of thrombolytic therapy and adjunctive antithrombotic regimens in acute ST-segment elevation myocardial infarction. Cohen, M., Arjomand, H., Pollack, C.V. Am. J. Emerg. Med (2004) [Pubmed]
  20. Intra-aortic balloon counterpulsation in US and non-US centres: results of the Benchmark Registry. Cohen, M., Urban, P., Christenson, J.T., Joseph, D.L., Freedman, R.J., Miller, M.F., Ohman, E.M., Reddy, R.C., Stone, G.W., Ferguson, J.J. Eur. Heart J. (2003) [Pubmed]
  21. The safety and efficacy of subcutaneous enoxaparin versus intravenous unfractionated heparin and tirofiban versus placebo in the treatment of acute ST-segment elevation myocardial infarction patients ineligible for reperfusion (TETAMI): a randomized trial. Cohen, M., Gensini, G.F., Maritz, F., Gurfinkel, E.P., Huber, K., Timerman, A., Krzeminska-Pakula, M., Danchin, N., White, H.D., Santopinto, J., Bigonzi, F., Hecquet, C., Vittori, L. J. Am. Coll. Cardiol. (2003) [Pubmed]
  22. Prospective evaluation of clinical outcomes after acute ST-elevation myocardial infarction in patients who are ineligible for reperfusion therapy: preliminary results from the TETAMI registry and randomized trial. Cohen, M., Gensini, G.F., Maritz, F., Gurfinkel, E.P., Huber, K., Timerman, A., Krzeminska-Pakula, M., Santopinto, J., Hecquet, C., Vittori, L. Circulation (2003) [Pubmed]
 
WikiGenes - Universities